Cancer Research and Treatment

Original Article

Breast cancer

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy: Eun-Gyeong Lee, Dong-Eun Lee, Hyun hee Kim, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Heejung Chae, Sung Hoon Sim, Keun Seok Lee, Youngmee Kwon, So-Youn Jung; Cancer Res Treat. 2023;55(2):542-550. Published online September 8, 2022; DOI: https://doi.org/10.4143/crt.2022.834

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors.
Materials and Methods
We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center in Goyang, Korea from April 2016 to October 2019. We retrospectively collected the clinicopathologic information and AR expression results and analyzed the data according to cancer stage, hormonal receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, tumor subtype, and pCR.
Results
Among the 624 breast cancer patients, 529 (84.8%) were AR-positive (AR+) patients and 95 (15.2%) were AR-negative (AR–) patients. AR+ patients showed more estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, HER2-positivity, and HR-positive and HER2-negative (HR+/HER2–) subtype. The rate of pCR was 31.4% (196/624). AR– patients had a significantly higher rate of pCR than AR+ patients (AR– 43.2% vs. AR+ 29.3%, p=0.007). The tumor factors associated with pCR were early stage, histologic grade 3, ER-negative, PR-negative, AR-negative, HER2-positive, and high Ki-67 values. In univariable analysis, AR+ significantly decreased the state of pCR (odds ratio, 0.546; 95% confidence interval, 0.349 to 0.853; p=0.008). According to tumor subtype, AR– tumor showed higher pCR rate in HR+/HER2– subtype (AR– 28.6% vs. AR+ 7.3%, p=0.022).
Conclusion
AR expression is predominant in the HR+/HER2– subtype. AR– is significantly associated with the pCR rate in breast cancer patients, especially within HR+/HER2– subtype. When determining neoadjuvant chemotherapy for the HR+/HER2– subtype, AR expression can be considered as a pCR predictive marker.

Citations

Citations to this article as recorded by

The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response
Di Ai, Eliel N Arrey, Lauren M Postlewait, Yuan Gao, Xiaoxian Li
Histopathology.2025;[Epub] CrossRef
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Athina Stravodimou, Ioannis A. Voutsadakis
Expert Review of Anticancer Therapy.2024; 24(3-4): 117. CrossRef
Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
Miseon Lee, Tae-Kyung Yoo, Byung Joo Chae, Ahwon Lee, Yoon Jin Cha, Jieun Lee, Sung Gwe Ahn, Jun Kang
Scientific Reports.2024;[Epub] CrossRef
Evaluating the Clinico-Pathological Relationship Between Stromal Tumor-Infiltrating Lymphocytes and Androgen Receptor Expression Across Molecular Subtypes of Invasive Breast Carcinoma
Adil Aziz Khan, Sana Ahuja, Kiruthikasri G., Sufian Zaheer
Indian Journal of Surgical Oncology.2024; 15(4): 802. CrossRef
Biomarkers and translational research approaches in breast cancer—an update
Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch
memo - Magazine of European Medical Oncology.2023; 16(1): 42. CrossRef
Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuanglong Cai, Xu Liu, Jie Meng, Jin Zhang
Discover Oncology.2023;[Epub] CrossRef

5,462 View
178 Download
6 Web of Science
6 Crossref

Case Report

A Rare Case of Phyllodes Tumor Metastasis to the Stomach Presenting as Anemia: Do Il Choi, Ho Seok Chi, Sang Ho Lee, Youngmee Kwon, Seog Yun Park, Sung Hoon Sim, In Hae Park, Keun Seok Lee; Cancer Res Treat. 2017;49(3):846-849. Published online September 1, 2016; DOI: https://doi.org/10.4143/crt.2016.188

Abstract PDF PubReader ePub

Metastasis of a phyllodes tumor to the stomach is an extremely rare condition with important clinical implications. A 44-year-old woman was initially diagnosed with a phyllodes tumor in her right breast in 2008, and subsequently presented to an outpatient clinic with dizziness on December 16, 2013. We found that she had severe anemia (hemoglobin levels, 6.7 g/dL), and we quickly performed esophagogastroduodenoscopy to identify the cause. This procedure revealed large ulcerofungating masses with active bleeding in the stomach. Histopathological examination revealed that the masses were consistent with phyllodes tumor metastases. In patients with a metastatic phyllodes tumor presenting as anemia, gastric metastasis should be considered as one of the differential diagnoses because overlooking the possibility might have dire consequences if cytotoxic chemotherapy were administered.

Citations

Citations to this article as recorded by

Unusual Metastatic Sites in Malignant Phyllodes Tumor Detected on FDG PET/CT
Wai Ip Li, Koon Kiu Ng, Ting Kun Au Yong, Boom Ting Kung
World Journal of Nuclear Medicine.2024; 23(02): 147. CrossRef
NKILA is a novel suppressor of local recurrence in women breast malignant phyllodes tumor patients via inhibition of the NF-κB pathway
Ying Mi, Le Yan, Haiyun Jin, Ming Jin, Di Zhu, Hongyan Huang, Kai Han, Jibo Huang
Heliyon.2024; 10(13): e33259. CrossRef
A rare case of metastatic malignant phyllodes tumor with osteosarcomatous differentiation presenting with intestinal obstruction
Neelam R. Bhandari, Manjusha M. Karegar, Pradeep Vaideeswar
Indian Journal of Pathology and Microbiology.2023; 66(1): 184. CrossRef
Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study
Naiquan Liu, Ye Kang, Ningxin Qu, Chenhui Kong, Ye Han
BMC Cancer.2023;[Epub] CrossRef
Metastasis to the stomach: a systematic review
Arturan Ibrahimli, Altay Aliyev, Aykhan Majidli, Aysegul Kahraman, Aysuna Galandarova, Emil Khalilzade, Heydar Mammadli, Kamran Huseynli, Karam Assaf, Cagatay Kilinc, Nijat Muradov, Omer F. Alisan, Sabir Abdullayev, Yeliz I. Sahin, Elgun Samadov
F1000Research.2023; 12: 1374. CrossRef
Significant Antitumor Activity of Pazopanib in a Patient with PDGFRB-Mutated Metastatic Phyllodes Tumor: a Case Report
Mieko Ochi, Shingo Miyamoto, Keita Nakao, Yoshiaki Furuhata, Yusuke Tabei, Shunsuke Ichi, Yuan Bae, Toshio Kumasaka, Shingo Kato, Hideo Kunitoh
SN Comprehensive Clinical Medicine.2021; 3(3): 901. CrossRef
Malignant phyllodes tumor of the breast: case report, tumor characteristics, treatment approach
Łukasz Strzępek, Patrycja Ciesielska, Katarzyna Karakiewicz-Krawczyk, Aleksandra Czerw
Breast Cancer Management.2021;[Epub] CrossRef
A giant malignant phyllodes tumor of breast post mastectomy with metastasis to stomach manifesting as anemia: a case report and review of literature
Hui-Pu Liu, Wen-Yen Chang, Chin-Wen Hsu, Shan-Tao Chien, Zheng-Yi Huang, Wen-Ching Kung, Ping-Hung Liu
BMC Surgery.2020;[Epub] CrossRef
Distant metastases in phyllodes tumours of the breast: an overview
Valerie Cui Yun Koh, Aye Aye Thike, Puay Hoon Tan
Applied Cancer Research.2017;[Epub] CrossRef
Atypical Distant Metastasis of Breast Malignant Phyllodes Tumors: A Case Report and Literature Review
Tiphaine de Foucher, Hélène Roussel, Mikael Hivelin, Léa Rossi, Caroline Cornou, Anne-Sophie Bats, Myriam Deloménie, Fabrice Lécuru, Charlotte Ngô
Case Reports in Obstetrics and Gynecology.2017; 2017: 1. CrossRef

10,514 View
180 Download
10 Web of Science
10 Crossref

First
Prev
Page of 1
Next
Last

Search